US20160009818A1 - Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics - Google Patents

Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics Download PDF

Info

Publication number
US20160009818A1
US20160009818A1 US14/772,336 US201414772336A US2016009818A1 US 20160009818 A1 US20160009818 A1 US 20160009818A1 US 201414772336 A US201414772336 A US 201414772336A US 2016009818 A1 US2016009818 A1 US 2016009818A1
Authority
US
United States
Prior art keywords
antibody
tfpi
comprises seq
isolated human
chain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/772,336
Other languages
English (en)
Inventor
John E. Murphy
George Wang
Ruth Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Priority to US14/772,336 priority Critical patent/US20160009818A1/en
Publication of US20160009818A1 publication Critical patent/US20160009818A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • an agent that significantly provides protection and requires relatively infrequent administration is most desired.
  • the optimal therapy should provide protection via weekly or less frequent dosing.
  • therapies administered intravenously (i.v.) or subcutaneously (s.c.) may be a reality over the next 3-4 years. Therefore, an agent that is administered i.v. or s.c. should provide a superior administration profile with commensurate protection.
  • subcutaneous administration could also offer a significant value to the future treatment landscape due to the reduced invasiveness of this approach.
  • Another major issue for current hemophilia therapy is the development of inhibitory antibodies against Factor VIII or Factor IX. Approximately 25% of FVIII treated patients generate inhibitors, or neutralizing antibodies against FVIII. Inhibitors are also found in FIX treated patients, although less frequently. The development of inhibitors significantly reduces the effectiveness of replacement therapy and provides a challenge for managing bleeds in hemophilia patients.
  • the current treatment for bleeds in patients with inhibitors to FVIII or FIX is bypass therapy with recombinant Factor VIIa or plasma derived FEIBA.
  • the half-life of rFVIIa is quite short ( ⁇ 2 hours) and thus prophylactic treatment in these patients is uncommon [Blanchette, Haemophilia 16 (supplement 3): 46-51, 2010].
  • TFPI Tissue Factor Pathway Inhibitor
  • PWH Persons with Hemophilia
  • mAb monoclonal antibody
  • Antibodies that inhibit TFPI also have significant bioavailability following subcutaneous injection.
  • anti-TFPI monoclonal antibody therapy would meet an important unmet medical need for subcutaneous, long acting hemostatic protection for PWH and PWH with inhibitors.
  • TMDD target mediated drug disposition
  • This need would be met by an anti-TFPI antibody having improved characteristics that may be administered intravenously or subcutaneously, and at a reduced frequency, preferably once weekly or less.
  • TMDD is reduced by creating a variant anti-TFPI antibody having reduced affinity at pH 6.0 relative to pH 7.4.
  • An anti-TFPI antibody may be taken into cells in complex with its target, TFPI, through receptors involved in TFPI clearance.
  • One receptor identified by Narita et al.
  • One method for disruption of an antigen: antibody complex at lower pH is to substitute histidine residues near the antibody:antigen interaction surface.
  • the amino acid histidine (His) is protonated at low pH, near pH 6.0, and thus, a residue that is neutral at pH 7.4 acquires a positive charge at pH 6.0. This can lead to charge repulsion with other amino acids and a desirable degree of disruption or destabilization at the antibody:antigen interface.
  • pH sensitive anti-TFPI mAb variants bind to the neonatal FcRN receptor and are recycled to the plasma.
  • a combination between a pH sensitive TFPI-binding site and a Fc domain with increased affinity for FcRN at low pH would have a synergistic effect that increases half-life, reduces the injection burden to patients, and reduces the cost of goods.
  • FIG. 1 shows alignment of amino acid sequences for 2A8-g200 and mutated anti-TFPI mAbs suitable for histidine substitution (SEQ ID NOs for these sequences can be found in Table 1).
  • CDR regions 1—3 are indicated.
  • FIG. 2 shows synthesis and subcloning of a 2A8-g200 Fab Histidine Scanning Library.
  • the CDR1-3 regions are indicated with a dashed line.
  • Underlined amino acid residues indicate the position of contact residues to TFPI.
  • An asterisk (*) indicates a proposed His mutation site.
  • FIG. 3 shows dissociation constants at two pHs for the improved antibodies with exemplary histidine mutations: A. L-L27H and B. L-Y31 H. Surface plasmon resonance (Biacore T200) was used to measure the dissociation rate of the antibodies.
  • FIG. 4 shows pK profiles observed in Hem A mouse plasma over time for several monoclonal antibodies at concentrations of 2 mg/kg: 2A8-g200 (- -), histidine substituted monoclonal antibodies TPP2256 (L-Y31 H/Y49H) (-.- -.-) and TPP2259 (L-Y31 H) (- -).
  • Pharmacokinetic parameters of the antibodies were determined after intravenous (i.v.) bolus administration to HemA mouse at 2 mg/kg.
  • tissue factor pathway inhibitor or “TFPI” as used herein refers to any variant, isoform and species homolog of human TFPI that is naturally expressed by cells.
  • TFPI tissue factor pathway inhibitor
  • the binding of an antibody of the invention to TFPI reduces the blood clotting time.
  • an “antibody” refers to a whole antibody and any antigen binding fragment (i.e., “antigen-binding portion”) or single chain thereof.
  • the term includes a full-length immunoglobulin molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes, or an immunologically active portion of an immunoglobulin molecule, such as an antibody fragment, that retains the specific binding activity.
  • an antibody fragment binds with the same antigen that is recognized by the full-length antibody. For example, an anti-TFPI monoclonal antibody fragment binds to an epitope of TFPI.
  • the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
  • binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V L , V H , C L and C H1 domains; (ii) a F(ab′) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V H and C H1 domains; (iv) a Fv fragment consisting of the V L and V H domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a V H domain; (vi) an isolated complementarity determining region (CDR); (vii) minibodies, diaboidies, triabodies, tetrabodies, and
  • V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
  • single chain Fv single chain Fv
  • Such single chain antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody.
  • an antigen binding fragment may be encompassed in an antibody mimetic.
  • antibody mimetic or “mimetic” as used herein is meant a protein that exhibits binding similar to an antibody but is a smaller alternative antibody or a non-antibody protein. Such antibody mimetic may be comprised in a scaffold.
  • scaffold refers to a polypeptide platform for the engineering of new products with tailored functions and characteristics.
  • inhibits binding and “blocks binding” (e.g., referring to inhibition/blocking of binding of TFPI ligand to TFPI) are used interchangeably and encompass both partial and complete inhibition or blocking. Inhibition and blocking are also intended to include any measurable decrease in the binding affinity of TFPI to a physiological substrate when in contact with an anti-TFPI antibody as compared to TFPI not in contact with an anti-TFPI antibody, e.g., the blocking of the interaction of TFPI with factor Xa or blocking the interaction of a TFPI-factor Xa complex with tissue factor, factor VIIa or the complex of tissue factor/factor VIIa by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%.
  • Therapeutic antibodies have been made through hybridoma technology described by Koehler and Milstein in “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256, 495-497 (1975). Fully human antibodies may also be made recombinantly in prokaryotes and eukaryotes. Recombinant production of an antibody in a host cell rather than hybridoma production is preferred for a therapeutic antibody. Recombinant production has the advantages of greater product consistency, likely higher production level, and a controlled manufacture that minimizes or eliminates the presence of animal-derived proteins. For these reasons, it is desirable to have a recombinantly produced monoclonal anti-TFPI antibody.
  • monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • therapeutic antibodies for human diseases have been generated using genetic engineering to create murine, chimeric, humanized or fully human antibodies.
  • Murine monoclonal antibodies were shown to have limited use as therapeutic agents because of a short serum half-life, an inability to trigger human effector functions, and the production of human anti-mouse-antibodies (Brekke and Sandlie, “Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-first Century,” Nature 2, 53, 52-62, Jan. 2003).
  • Chimeric antibodies have been shown to give rise to human anti-chimeric antibody responses. Humanized antibodies further minimize the mouse component of antibodies. However, a fully human antibody avoids the immunogenicity associated with murine elements completely. Thus, there is a need to develop antibodies that are human or humanized to a degree necessary to avoid the immunogenicity associated with other forms of genetically engineered monoclonal antibodies.
  • chronic prophylactic treatment such as would be required for hemophilia treatment with an anti-TFPI monoclonal antibody has a high risk of development of an immune response to the therapy if an antibody with a murine component or murine origin is used due to the frequent dosing required and the long duration of therapy. For example, antibody therapy for hemophilia A may require weekly dosing for the lifetime of a patient.
  • human monoclonal antibody refers to antibodies displaying a single binding specificity which have at least portions of variable and constant regions derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • These human antibodies include chimeric antibodies, such as mouse/human and humanized antibodies that retain non-human sequences.
  • an “isolated antibody,” as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds to TFPI is substantially free of antibodies that bind antigens other than TFPI).
  • An isolated antibody that binds to an epitope, isoform or variant of human TFPI may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., TFPI species homologs).
  • an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • specific binding refers to antibody binding to a predetermined antigen.
  • the antibody binds with an affinity of at least about 10 5 and binds to the predetermined antigen with an affinity that is higher, for example at least two-fold greater, than its affinity for binding to an irrelevant antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.
  • an irrelevant antigen e.g., BSA, casein
  • an antibody recognizing an antigen and “an antibody specific for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen.”
  • high affinity for an IgG antibody refers to a binding affinity of at least about 10 7 , in some embodiments at least about 10 8 , in some embodiments at least about 10 9 , 10 10 , 10 11 or greater, e.g., up to 10 13 or greater.
  • “high affinity” binding can vary for other antibody isotypes.
  • “high affinity” binding for an IgM isotype refers to a binding affinity of at least about 1.0 ⁇ 10 7 .
  • isotype refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.
  • CDR complementarity-determining region
  • CDR1 CDR2
  • CDR3 CDR3
  • An antigen-binding site may include six CDRs, comprising the CDR regions from each of a heavy and a light chain V region.
  • “conservative substitutions” refers to modifications of a polypeptide that involve the substitution of one or more amino acids for amino acids having similar biochemical properties that do not result in loss of a biological or biochemical function of the polypeptide.
  • a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine. It is envisioned that the antibodies of the present invention may have conservative amino acid substitutions and still retain activity.
  • substantially homology indicates that two polypeptides, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate amino acid insertions or deletions, in at least about 80% of amino acids, usually at least about 85%, preferably about 90%, 91%, 92%, 93%, 94%, or 95%, more preferably at least about 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, or 99.5% of the amino acids.
  • the invention includes polypeptide sequences having substantial homology to the specific amino acid sequences recited herein.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, such as the AlignXTM module of VectorNTITM (Invitrogen Corp., Carlsbad, Calif.).
  • AlignXTM the default parameters of multiple alignment are: gap opening penalty: 10; gap extension penalty: 0.05; gap separation penalty range: 8; % identity for alignment delay: 40.
  • Another method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence can be determined using the CLUSTALW computer program (Thompson et al., Nucleic Acids Research, 1994, 2(22): 4673-4680), which is based on the algorithm of Higgins et al., (Computer Applications in the Biosciences (CABIOS), 1992, 8(2): 189-191).
  • CLUSTALW computer program Thimpson et al., Nucleic Acids Research, 1994, 2(22): 4673-4680
  • Higgins et al. Computer Applications in the Biosciences (CABIOS), 1992, 8(2): 189-191
  • the query and subject sequences are both DNA sequences.
  • the result of said global sequence alignment is in percent identity.
  • compositions comprising therapeutically effective amounts of anti-TFPI monoclonal antibody and a pharmaceutically acceptable carrier.
  • therapeutically effective amount means an amount of an anti-TFPI monoclonal antibody variant or of a combination of such antibody and factor VIII or factor IX that is needed to effectively increase the clotting time in vivo or otherwise cause a measurable benefit in vivo to a patient in need. The precise amount will depend upon numerous factors, including, but not limited to the components and physical characteristics of the therapeutic composition, intended patient population, individual patient considerations, and the like, and can readily be determined by one skilled in the art.
  • “Pharmaceutically acceptable carrier” is a substance that may be added to the active ingredient to help formulate or stabilize the preparation and causes no significant adverse toxicological effects to the patient.
  • examples of such carriers are well known to those skilled in the art and include water, sugars such as maltose or sucrose, albumin, salts such as sodium chloride, etc.
  • Other carriers are described for example in Remington's Pharmaceutical Sciences by E. W. Martin. Such compositions will contain a therapeutically effective amount of at least one anti-TFPI monoclonal antibody.
  • compositions include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the use of such media and agents for pharmaceutically active substances is known in the art.
  • the composition is preferably formulated for parenteral injection.
  • the composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • some methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the human monoclonal antibody can be used for therapeutic purposes for treating genetic and acquired deficiencies or defects in coagulation.
  • the human monoclonal antibodies may be used to block the interaction of TFPI with FXa, or to prevent TFPI-dependent inhibition of the TF/FVIIa activity.
  • the human monoclonal antibody may also be used to restore the TF/FVIIa-driven generation of FXa to bypass the insufficiency of FVIII- or FIX-dependent amplification of FXa.
  • the human monoclonal antibodies have therapeutic use in the treatment of disorders of hemostasis such as thrombocytopenia, platelet disorders and bleeding disorders (e.g., hemophilia A, hemophilia B and hemophlia C). Such disorders may be treated by administering a therapeutically effective amount of the anti-TFPI monoclonal antibody variant to a patient in need thereof.
  • the human monoclonal antibodies also have therapeutic use in the treatment of uncontrolled bleeds in indications such as trauma and hemorrhagic stroke.
  • a method for shortening the bleeding time comprising administering a therapeutically effective amount of an anti-TFPI human monoclonal antibody variant of the invention to a patient in need thereof.
  • the antibodies can be used as monotherapy or in combination with other therapies to address a hemostatic disorder.
  • co-administration of one or more variant antibodies of the invention with a clotting factor such as factor VIIa, factor VIII or factor IX is believed useful for treating hemophilia.
  • Factor VIII or Factor IX are administered in the substantial absence of Factor VII.
  • Factor VII includes factor VII and factor VIIa.
  • a method for treating genetic and acquired deficiencies or defects in coagulation comprises administering (a) a first amount of a variant monoclonal antibody that binds to human tissue factor pathway inhibitor and (b) a second amount of factor VIII or factor IX, wherein said first and second amounts together are effective for treating said deficiencies or defects.
  • a method for treating genetic and acquired deficiencies or defects in coagulation comprises administering (a) a first amount of a monoclonal antibody variant that binds to human tissue factor pathway inhibitor and (b) a second amount of factor VIII or factor IX, wherein said first and second amounts together are effective for treating said deficiencies or defects, and further wherein factor VII is not coadministered.
  • the invention also includes a pharmaceutical composition comprising a therapeutically effective amount of the combination of a monoclonal antibody variant of the invention and factor VIII or factor IX, wherein the composition does not contain factor VII.
  • combination therapies are likely to reduce the necessary infusion frequency of the clotting factor.
  • co-administration or combination therapy is meant administration of the two therapeutic drugs each formulated separately or formulated together in one composition, and, when formulated separately, administered either at approximately the same time or at different times, but over the same therapeutic period.
  • one or more antibody variants described herein can be used in combination to address a hemostatic disorder.
  • co-administration of two or more of the antibody variants described herein is believed useful for treating hemophilia or other hemostatic disorder.
  • compositions may be parenterally administered to subjects suffering from hemophilia A or B at a dosage and frequency that may vary with the severity of the bleeding episode or, in the case of prophylactic therapy, may vary with the severity of the patient's clotting deficiency.
  • compositions may be administered to patients in need as a bolus or by continuous infusion.
  • a bolus administration of an antibody variant present as a Fab fragment may be in an amount of from 0.0025 to 100 mg/kg body weight, 0.025 to 0.25 mg/kg, 0.010 to 0.10 mg/kg or 0.10-0.50 mg/kg.
  • an antibody variant present as an Fab fragment may be administered at 0.001 to 100 mg/kg body weight/minute, 0.0125 to 1.25 mg/kg/min., 0.010 to 0.75 mg/kg/min., 0.010 to 1.0 mg/kg/min. or 0.10-0.50 mg/kg/min.
  • dosage amounts may be about 1-10 mg/kg body weight, 2-8 mg/kg, or 5-6 mg/kg.
  • Such full-length antibodies would typically be administered by infusion extending for a period of thirty minutes to three hours.
  • the frequency of the administration would depend upon the severity of the condition. Frequency could range from three times per week to once every two weeks to six months.
  • compositions may be administered to patients via subcutaneous injection.
  • a dose of 10 to 100 mg anti-TFPI antibody can be administered to patients via subcutaneous injection weekly, biweekly or monthly.
  • Variant monoclonal antibodies to human tissue factor pathway inhibitor are provided. Further provided are the isolated nucleic acid molecules encoding the same. Pharmaceutical compositions comprising the variant anti-TFPI monoclonal antibodies and methods of treatment of genetic and acquired deficiencies or defects in coagulation such as hemophilia A and B are also provided. Also provided are methods for shortening the bleeding time by administering an anti-TFPI monoclonal antibody to a patient in need thereof. Methods for producing a variant monoclonal antibody that binds human TFPI according to the present disclosure are also provided.
  • the therapeutic composition comprises antibody having binding regions that differ from the sequence of a parenteral TFPI binding antibody by the intentional [illegible] selection or engineering of one or more substitutions of the amino acid histidine (H, HIS) for at least one native amino acid as defined in the parental sequence.
  • the amino acid change confers longer circulating half-life T1 ⁇ 2 relative to the parental molecule.
  • An antibody specific for TFPI that binds to TFPI with at least 20% lower efficiency at pH 6.0 than at pH 7.0 is disclosed and that shows an improvement in circulating T1 ⁇ 2 of approximately 400%.
  • the beneficial effect reducing TMDD is demonstrated for an antibody or antibody binding region that differs from the sequence of a target antibody such as 2A8-g200 or 4B7-gB9.7 by the substitution of the amino acid histidine (H, HIS) for at least one native amino acid as defined relative to the parental sequence.
  • H, HIS amino acid histidine
  • a variant of 2A8-g200 may have any one of the following substitutions: VL-Y31 H, VH-Y102H, VH-Y100H, VH-Y32H, VL-F48H, VL-S50H, VL-Y49H, VL-L27H, VL-V45H, VL-W90H and combinations thereof.
  • FIG. 1 shows amino acid sequence information for 2A8-g200 and 4B7-gB9.7, as well as other 2A8 and 4B7 variants described in WO 2011/109452.
  • Table 1 shows the corresponding SEQ ID NOs for the variable heavy and variable light chains for the 2A8 and 4B7 variants shown in FIG. 1 .
  • FIG. 2 shows the location of possible His mutations for: A. 2A8-g200 (designated as A200 in FIG. 2A ) variable heavy chain; B. 2A8-g200 (designated as A200 in FIG. 2B ) variable light chain; C. 4B7-gB9.7 variable heavy chain; and D. 4B7-gB9.7 variable light chain.
  • A. 2A8-g200 designated as A200 in FIG. 2A
  • B. 2A8-g200 designated as A200 in FIG. 2B
  • C C. 4B7-gB9.7 variable heavy chain
  • D 4B7-gB9.7 variable light chain.
  • One histidine residue was substituted for each of the amino acids in either 1) a contact residue to TFPI as indicated by an underlined amino acid in FIG.
  • a 2A8-g200 Fab histidine scanning library was synthesized.
  • the library contained 69 members.
  • the 2A8-g200 Fab histidine library was cloned into a bacterial expression vector and the amino acid sequences were verified.
  • Human TFPI 1 ⁇ g/ml
  • Expression media 100 ⁇ l, from each member of the His scan library, was added to two wells on the plate, in a pair wise fashion. The plate was incubated on a shaker at room temperature for 1 hr. The plate was washed 3 ⁇ with PBST. PBS (pH 7.0) was added to one well of the pair, 100 mM pH6.0 Citrate buffer was added to the second well of the same pair. The plate was incubated at 37° C. with shaking for one hr. The plate was washed 3 ⁇ with PBST and developed using amplex red. A pH 7.0/pH 6.0 ratio was established to rank the sensitive muteins. The ratio for wild type 2A8-g200 Fab was 1.0. The 10 clones that had a ratio greater than 1.78 between pH 7.0 and pH 6.0 are shown in Table 2 below.
  • Purified 2A8-g200 variants in Fab format were tested using surface plasmon resonance (Biacore).
  • Surface plasmon resonance (Biacore T200) was used to measure the dissociation rate of the antibodies.
  • Human TFPI American Diagnostica
  • Biacore T200 was used to measure the dissociation rate of the antibodies.
  • Human TFPI American Diagnostica
  • CM4 or CM5 chip was amine coupled on a CM4 or CM5 chip using the method suggested by Biacore, resulting in 100 to 300 RU of immobilized TFPI.
  • Purified 2A8-g200 variants were injected, following by 40-minute dissociation either at pH7.4 or pH6.0 buffer.
  • the antibodies were diluted in HBS-P buffer at different concentrations and the flow rate was set to 50 ⁇ l/min. After each round of antibody injection, the chip was regenerated by injecting 90 ⁇ l of pH 1.5 glycine.
  • the data set was evaluated using BIAevaluation Software.
  • the dissociation constant (kd) for each 2A8-g200 variant antibody was determined by using a model with the following equation:
  • R is the response at time t
  • R 0 is the response at time t 0 . ⁇ the start of dissociation, offset allows for a residual response at the end of complete dissociation.
  • a ratio of kd at pH 6.0 to kd at pH 7.4 was calculated for each 2A8-g200 variant.
  • a mutation with observed ratio of 2 was considered as pH-sensitive mutation and could be used for construction of IgG variants of 2A8-g200.
  • Pharmacokinetic parameters of the antibodies were determined after intravenous (i.v.) bolus administration to HemA mouse at 2 mg/kg. All the pharmacokinetic parameters were calculated using WinNonLin software version 5.3.1 (Pharsight Corporation, Mountain View, Calif.) non-compartmental model.
  • the effect of histidine mutations on the observed half-life of anti-TFPI monoclonal antibodies in mouse plasma is shown in FIG. 4 .
  • 2A8-g200 with the histidine mutations TPP2256 (L-Y31 H/Y49H) and TPP2259 (L-Y31 H) increased the observed pK profiles over a 500 hour time span as compared to the corresponding pK profile of 2A8-g200 without any histidine substitution.
  • Table 3 quantifies the increases in half-life observed in the data of FIG. 4 .
  • the above designated antibodies that reduce TFPI mediated TMDD and have a prolonged T1 ⁇ 2 would lead to less frequent dosing and reduce the amount of material needed per dose. Furthermore, the need for a lower dose may also make feasible subcutaneous dosing where the dosing volume becomes a limiting step, a process by which the antibody is removed from circulation due to its interaction with a rapidly cleared target or by being sequestered from the plasma due to its co-localization with its target.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US14/772,336 2013-03-15 2014-03-14 Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics Abandoned US20160009818A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/772,336 US20160009818A1 (en) 2013-03-15 2014-03-14 Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798261P 2013-03-15 2013-03-15
US14/772,336 US20160009818A1 (en) 2013-03-15 2014-03-14 Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
PCT/US2014/029048 WO2014144577A1 (en) 2013-03-15 2014-03-14 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029048 A-371-Of-International WO2014144577A1 (en) 2013-03-15 2014-03-14 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/962,624 Continuation US20180282430A1 (en) 2013-03-15 2018-04-25 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Publications (1)

Publication Number Publication Date
US20160009818A1 true US20160009818A1 (en) 2016-01-14

Family

ID=50928243

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/213,278 Active 2034-07-09 US9556280B2 (en) 2013-03-15 2014-03-14 Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
US14/772,336 Abandoned US20160009818A1 (en) 2013-03-15 2014-03-14 Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
US15/962,624 Abandoned US20180282430A1 (en) 2013-03-15 2018-04-25 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/213,278 Active 2034-07-09 US9556280B2 (en) 2013-03-15 2014-03-14 Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/962,624 Abandoned US20180282430A1 (en) 2013-03-15 2018-04-25 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Country Status (18)

Country Link
US (3) US9556280B2 (el)
EP (1) EP2970497B1 (el)
JP (4) JP6454678B2 (el)
CN (2) CN105452298B (el)
CA (1) CA2906128A1 (el)
CY (1) CY1120210T1 (el)
DK (1) DK2970497T3 (el)
ES (1) ES2657304T3 (el)
HK (1) HK1218128A1 (el)
HR (1) HRP20180078T1 (el)
HU (1) HUE037907T2 (el)
LT (1) LT2970497T (el)
NO (1) NO3022387T3 (el)
PL (1) PL2970497T3 (el)
PT (1) PT2970497T (el)
RS (1) RS56814B1 (el)
SI (1) SI2970497T1 (el)
WO (1) WO2014144577A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
MX358220B (es) 2011-11-30 2018-08-10 Chugai Pharmaceutical Co Ltd Portador que contiene fármaco en la célula para formar el inmunocomplejo.
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP4279128A3 (en) * 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
KR20230074843A (ko) 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
MX2021004120A (es) 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110111406A1 (en) * 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8361469B2 (en) * 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101807894B1 (ko) * 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
PL2694544T3 (pl) 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
CN104185474B (zh) * 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
JP6309521B2 (ja) * 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
BR112015003464B1 (pt) * 2012-08-15 2022-01-18 Lucid, Inc Sistemas e processos para formação de imagens de tecido
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110111406A1 (en) * 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8361469B2 (en) * 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor

Also Published As

Publication number Publication date
CA2906128A1 (en) 2014-09-18
US20180282430A1 (en) 2018-10-04
PL2970497T3 (pl) 2018-05-30
JP6454678B2 (ja) 2019-01-16
CN105452298A (zh) 2016-03-30
HK1218128A1 (zh) 2017-02-03
NO3022387T3 (el) 2018-08-25
JP2020079250A (ja) 2020-05-28
SI2970497T1 (en) 2018-04-30
PT2970497T (pt) 2018-01-30
EP2970497A1 (en) 2016-01-20
JP2021107436A (ja) 2021-07-29
ES2657304T3 (es) 2018-03-02
WO2014144577A1 (en) 2014-09-18
US9556280B2 (en) 2017-01-31
DK2970497T3 (da) 2018-01-29
JP6697064B2 (ja) 2020-05-20
HUE037907T2 (hu) 2018-09-28
CY1120210T1 (el) 2018-12-12
JP2019069973A (ja) 2019-05-09
EP2970497B1 (en) 2017-10-25
JP2016514683A (ja) 2016-05-23
HRP20180078T1 (hr) 2018-03-09
RS56814B1 (sr) 2018-04-30
CN105452298B (zh) 2021-08-31
LT2970497T (lt) 2018-03-12
CN113788897A (zh) 2021-12-14
US20140275493A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US20180282430A1 (en) Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
JP6114326B2 (ja) 組織因子経路阻害因子に対する抗体
JP7550251B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
US12084516B2 (en) Anti-C5 antibody combinations and uses thereof
US20200223932A1 (en) Therapeutic Anti-CD40 Ligand Antibodies
TW201542226A (zh) 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
KR20220007128A (ko) 항-ｓｅｍａ３ａ 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도
WO2014072741A1 (en) Humanised antibody and method of production thereof
WO2023237928A2 (en) Igf1r antibodies
WO2023250507A1 (en) Methods for treating complement-mediated diseases
CN114786717A (zh) 稳定的水性抗-tfpi抗体制剂

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION